v3.25.2
INSTAPRIN ACQUISITION (Details Narrative) - Aspire Biopharma Inc [Member] - USD ($)
Mar. 28, 2022
Dec. 31, 2024
Restructuring Cost and Reserve [Line Items]    
Transaction costs   $ 316,800,000
Instaprin Pharmaceuticals Inc [Member]    
Restructuring Cost and Reserve [Line Items]    
Assets acquired $ 3,628,325  
Business acquistion percentage 20.00%  
Transaction costs $ 5,000,000  
Business acquistion description 10% from sales thereafter until the entire contingent purchase price obligation is satisfied. Additionally, ten percent (10%) of Buyer’s equity was to be delivered at Closing, in proportion to their equity holdings in the Company, to be issued to a Trustee for the former Instaprin Shareholders, along with an additional ten percent (10%) of Buyer’s equity to be issued to the Company’s service providers, pursuant to a stock incentive plan to be adopted.